The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.
[EN] INHIBITORS OF VAP-1<br/>[FR] INHIBITEURS DE VAP-1
申请人:ACUCELA INC
公开号:WO2020069330A3
公开(公告)日:2020-07-23
INHIBITORS OF VAP-1
申请人:Acucela Inc.
公开号:EP3856176A2
公开(公告)日:2021-08-04
ANTIBIOTIC COMPOUNDS
申请人:DISCUVA LTD.
公开号:US20190194179A1
公开(公告)日:2019-06-27
The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by,
Neisseria gonorrhoeae
.
COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
申请人:[en]NMD PHARMA A/S
公开号:WO2024121130A1
公开(公告)日:2024-06-13
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.